DEFR14A: Shuttle Pharmaceuticals Seeks Stockholder Approval for Reverse Stock Split, Equity Plan Amendment, and Convertible Note Issuance

Shuttle Pharmaceuticals is asking stockholders to approve a reverse stock split, an increase in shares reserved for its equity incentive plan, and the issuance of common stock upon conversion of convertible notes.

Summary

• Shuttle Pharmaceuticals Holdings, Inc. is seeking stockholder approval for several key proposals at its upcoming annual meeting on May 9, 2025.
• The proposals include electing five directors, ratifying the appointment of Forvis Mazars, LLP as the company's independent auditor, and approving executive compensation on an advisory basis.
• A significant proposal involves authorizing the Board of Directors to implement a reverse stock split within a range of 1-for-3 to 1-for-100 to regain compliance with Nasdaq listing requirements and to have the option for a further stock split if needed.
• The company is also seeking approval to amend its 2018 Equity Incentive Plan to increase the number of shares reserved for issuance by 5,000,000 shares.
• Additionally, stockholders will vote on approving the issuance of more than 19.99% of the company's common stock upon conversion of convertible notes issued in October 2024, as required by Nasdaq Listing Rule 5635(d).
• The Board of Directors recommends voting in favor of all proposals.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive developments in the clinical trial and management changes, the need for a reverse stock split and reliance on convertible notes raise concerns about the company's financial stability.

Positives

• The Phase 2 clinical trial for Ropidoxuridine is progressing well, with enrollment meeting expectations.
• The appointment of Christopher Cooper as interim CEO is expected to improve the company's capital markets and business capabilities.
• The addition of three new board members with business and legal backgrounds should provide valuable guidance.
• The recent $5.75 million capital raise will support the Phase 2 clinical trial and other corporate activities.
• Advancement of a robust development portfolio including therapeutics and diagnostics.

Negatives

• The company is not in compliance with Nasdaq's minimum bid price requirement, necessitating a potential reverse stock split.
• The company has a history of related party transactions, including loans from the CEO and his spouse.
• The company has a history of delinquent Section 16(a) reports.
• The company has incurred significant fees for professional audit services, totaling $676,081 in 2024.

Risks

• The reverse stock split may not result in a sustained increase in the per share price of the common stock.
• Delisting from Nasdaq could negatively impact the liquidity and trading volume of the common stock.
• The company's dependence on expanding access to capital markets poses a risk if funding is not secured.
• Clinical trials are subject to inherent risks, and there is no guarantee of successful outcomes.
• The company's pre-revenue status makes it vulnerable to financial instability.

Future Outlook

The company aims to finalize enrollment in its Phase 2 clinical trial later this year, with data readout expected in 2026. They also plan to submit applications for NIH funding and seek collaborations or joint ventures to support further development of selected preclinical assets.

Management Comments

• 'The biggest milestone achieved this past year was the successful launch of our Phase 2 trial of Ropidoxuridine and RT for treatment of patients with glioblastoma,' stated Anatoly Dritschilo, MD, Chairman of the Board of Directors.
• Dr. Dritschilo also expressed the company's mission to 'launch the next generation of drugs to improve outcomes and achieve more cures for cancer patients undergoing radiation treatments.'

Industry Context

Shuttle Pharmaceuticals is operating in the competitive oncology therapeutics and diagnostics market. The company's focus on radiation sensitizers and pretreatment diagnostic tests aligns with the industry's trend toward personalized medicine and improving cancer treatment outcomes.

Comparison to Industry Standards

• The company's Phase 2 trial enrollment rate appears promising compared to industry averages for similar oncology trials.
• The company's reliance on convertible notes for financing is a common practice among small-cap biotech companies, but it also carries risks related to dilution and debt repayment.
• The company's executive compensation structure is relatively lean compared to larger pharmaceutical companies, reflecting its developmental stage.

Management Changes

Corporate Governance

Related Party Transactions

• On September 14, 2022, we entered into a manufacturing agreement with TCG GreenChem, the U.S. subsidiary of TCG Lifesciences Pvt Ltd., a global contract research and manufacturing services company located in India. Dr. Chis Senanayake, one of our independent directors who resigned in February 2025, is CEO and CSO of TCG GreenChem and CSO of TCG Lifesciences Pvt Ltd.
• On September 4, 2024, the Company entered into a loan agreement with our then Chief Executive Officer, Dr. Anatoly Dritschilo, pursuant to which Dr. Dritschilo loaned the Company of $250,000 (principal), bearing interest at the rate of 12% per annum and which is repayable in 12 substantially equal monthly installments over a one-year period.
• On October 14, 2024, we entered into a securities purchase agreement with our then Chief Executive Officer (the Securities Purchase Agreement). Pursuant to the Securities Purchase Agreement, we issued a $250,000 5% original issue discount senior secured convertible note and warrants to purchase up to a total of 100,382 shares of common stock at an exercise price per share equal to $1.40 per share to Dr. Dritschilo.
• On March 5, 2025, the Company entered into a loan agreement with our Chief Executive Officer, Dr. Anatoly Dritschilo, pursuant to which Dr. Dritschilo loaned the Company of $75,000 (principal), bearing interest at the rate of 14% per annum and which is repayable with accrued interest in one month.

Stakeholder Impact

• Shareholders will be impacted by the potential reverse stock split and the issuance of new shares.
• Employees and directors may be affected by changes to the equity incentive plan.
• The company's ability to fund its clinical trials and operations will impact its long-term prospects for all stakeholders.

Next Steps

• Stockholders will vote on the proposals at the Annual Meeting on May 9, 2025.
• The Board of Directors will decide whether and when to implement the reverse stock split.
• The company will continue to execute its Phase 2 clinical trial and advance its development portfolio.

Key Dates

Keywords

reverse stock split, equity incentive plan, convertible notes, Ropidoxuridine, clinical trial, Nasdaq, proxy statement, corporate governance, pharmaceuticals, biotech